Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition

Kidney International

Volumn 55, Issue 6, 1999, Pages 2390-2396

  Qiu, Changbin ^a,b   Baylis, Chris ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bosentan; Efferent arteriolar resistance; Losartan; N monomethyl L arginine; Single nephron glomerular filtration rate; Vasoconstriction

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BOSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; INULIN; LOSARTAN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; TRITIUM;

ANIMAL EXPERIMENT; ARTERIOLE; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032991441     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00466.x     Document Type: Article

References (44)

1. 1. Baylis C, Harton P, Engels K: Endothelial derived relaxing factor (EDRF) controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1:875-881, 1990
2. 2. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142, 1991
3. 3. Rau L, Baylis C: Nitric oxide and the glomerulus. Kidney Int 48:20-32, 1995
4. 4. Baylis C, Qiu C: Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 49:1727-1731, 1996
5. 5. Baylis C, Engels K, Samsell L, Harton P: Renal effects of acute endothelial derived relaxing factor blockade are not mediated by angiotensin II. Am J Physiol 264:F74-F78, 1993
6. 6. Qiu C, Engels K, Baylis C: Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 6:1476-1481, 1995
7. 7. Deng A, Baylis C: Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol 264:F212-F215, 1993
8. 8. Zata R, De Nucci G: Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol 261:F360-F363, 1991
9. 9. De Nicola L, Blantz RC, Garbai FB: Nitric oxide and angiotensin II: Glomerular and tubular interaction in the rat. J Clin Invest 89:1248-1256, 1992
10. 10. Shultz PJ, Schorer AE, Rau L: Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol 258:F162-F167, 1990
11. 11. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC: Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J Clin Invest 83:336-342, 1989
12. 12. Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr: Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 85:1894-1898, 1992
13. 13. Richard V, Hogie M, Clozel M, Loffler B-M, Thuillez C: In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 91:771-775, 1995
14. 14. Kourembanas S, McQuillan LP, Leung GK, Faller DV: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92:99-104, 1993
15. 15. Boulanger C, Luscher TF: Release of endothelin from porcine aorta: Inhibition by endothelium-derived nitric oxide. J Clin Invest 85:587-590, 1990
16. 16. Sigmon DH, Beierwaltes WH: Angiotensin II: Nitric oxide interaction and the distribution of blood flow. Am J Physiol 265:R1276-R1283, 1993
17. 17. Baylis C, Harvey J, Engels K: Acute nitric oxide blockade amplifies the renal vasoconstrictor actions of angiotensin II. J Am Soc Nephrol 5:211-214, 1994
18. 18. Ichikawa I, Maddox DA, Cogan MC, Brenner BM: Dynamics of glomerular ultrafiltration in euvolemic Munich Wistar rats. Renal Physiol 1:121-131, 1978
19. 19. Baylis C, Deen WM, Myers BD, Brenner BM: Effects of some vasodilator drugs on transcapillary fluids exchange in renal cortex. Am J Physiol 230:1148-1158, 1976
20. 20. Baylis C: Immediate and long-term effects of pregnancy on glomerular function in the SHR. Am J Physiol 257:F1140-F1145, 1989
21. 21. Clozel M, Breu V, Gray GA, Kalina B, Loffler B-M, Burri K, Cassal J-M, Hirth G, Muller M, Neidhart W, Ramuz H: Pharmacological characterization of Bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235, 1994
22. 22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
23. 23. Munger K, Baylis C: Sex differences in renal hemodynamics in rats. Am J Physiol 254:F223-F231, 1988
24. 24. SAS Institute: SAS/STAT Guide (version 6). Cary, SAS Institute, 1983, pp 183-260
25. 25. Ito S, Ren Y: Evidence for the role of nitric oxide in macula densa control of glomerular hemodynamics. J Clin Invest 92:1093-1098, 1993
26. 26. Navar LG: Renal autoregulation: Perspectives from whole kidney and single nephron studies. Am J Physiol 234:F357-F370, 1978
27. 27. Baylis C: Acute interactions between endothelin and nitric oxide in control of renal hemodynamics. Clin Exp Pharmacol Physiol 26:253-257, 1999
28. 28. Ohishi K, Carmines PK, Inscho EW, Navar LG: EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol 263:F900-F906, 1992
29. 29. King AJ, Brenner BM, Anderson S: Endothelin: A potent renal and systemic vasoconstrictor peptide. Am J Physiol 256:F1051-F1058, 1989
30. 30. Kon V, Yoshioka T, Fogo A, Ichikawa I: Glomerular actions of endothelin in vivo. J Clin Invest 83:1762-1767, 1989
31. 31. Lanese DM, Yuan BH, McMurtry IF, Conger JD: Comparative sensitivities of isolated rat renal arterioles to endothelin. Am J Physiol 263:F894-F899, 1992
32. 32. Qiu C, Samsell L, Baylis C: Actions of endogenous endothelin on glomerular hemodynamics in the rat. Am J Physiol 269:R469-R473, 1995
33. 33. Saijonmaa O, Ristimaki A, Fyhrquist F: Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun 173:514-520, 1990
34. 34. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756, 1998
35. 35. Matsuura T, Miura K, Ebara T, Yukimura T, Yamanaka S, Kim S, Iwao H: Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol 122:81-86, 1997
36. 36. Goligorsky MS, Tsukahara H, Magazine H, Anderson TT, Malik AB, Bahou WF: Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 158:485-494, 1994
37. 37. Thompson A, Valeri CR, Lieberthal W: Endothelin receptor A blockade alters hemodymamic response to nitric oxide inhibition in rats. Am J Physiol 269:H743-H748, 1995
38. 38. Baylis C, Masilamani S, Losonczy G, Samsell L, Harton P, Engels K: Blood pressure (BP) and renal vasoconstrictor responses to acute blockade of nitric oxide: Persistence of renal vasoconstriction despite normalization of BP with either verapamil or sodium nitroprusside. J Pharmacol Exp Ther 274:1135-1141, 1995
39. 39. Zhang XZ, Baylis C: Endothelin mediates the renal vascular "memory" of a transient rise in perfusion pressure due to acute systemic NOS inhibition. Am J Physiol (in press)
40. 40. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 29:2-26, 1997
41. 41. Rabelink TJ, Kaasjager KAH, Stroes ESG, Koomans HA: Endthelin in renal pathophysiology: From experimental to therapeutic application. Kidney Int 50:1827-1833, 1996
42. 42. Van Heugten HA, Eskildsen-Helmond YE, De Jonge HW, Bezstarosti K, Lamers JM: Phosphoinositide-generated messengers in cardiac signal transduction. Mol Cell Biochem 157:5-14, 1996
43. 43. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, Harrison DG: Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 30:29-34, 1997
44. 44. Herizi A, Jover B, Bouriquet N, Mimran A: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 31:10-14, 1998